Farhan Ikhtiar

Mr. Farhan Ikhtiar


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
Farhan IkhtiarFarhan Ikhtiar
Farhan Ikhtiar
AJADIL JAMAL
ADIL JAMAL
SBSyed M. Safeer Mehdi Bokhari
Syed M. Safeer Mehdi Bokhari
Hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, represent a diverse group of blood cancers driven by complex oncogenic pathways and genetic aberrations. Despite advances in treatment, resistance and relapse remain significant clinical challenges. This review presents an integrative approach to blood cancer therapy, highlighting the convergence of precision medicine, CRISPR-based gene editing, immunotherapy (including CAR-T cells and immune checkpoint inhibitors), and targeted modulation of amino acid metabolism. We investigate the molecular pathways driving tumour development and resistance, highlighting how multi-omic profiling facilitates personalised therapy approaches. Recent breakthroughs in reprogramming immune responses and editing driver mutations have revolutionized therapeutic paradigms. Additionally, the metabolic dependencies of cancer cells, particularly in amino acid biosynthesis and catabolism, offer novel vulnerabilities. This meticulous synthesis outlines a framework for translational techniques that integrate molecular targeting with immunological and metabolic regulation to improve treatment effectiveness and surmount therapeutic resistance in haematologic malignancies.

27 February 2025 in Brazilian Journal of Science
Verified
Journal Article
Open access
PDF file
LILaraib Zafar Iqbal
Laraib Zafar Iqbal
Farhan IkhtiarFarhan Ikhtiar
Farhan Ikhtiar
MFMuhammad Usman Farooq
Muhammad Usman Farooq
MFMuhammad Faheem Faraz
Muhammad Faheem Faraz
TRTanzeela Riaz
Tanzeela Riaz
RURana Hissan Ullah
Rana Hissan Ullah
The nanoemulsion was prepared using ethanol (3%), the biosurfactant Tween 80 (5%), and water (80%), which together constituted 20% (v/v) of the nanoemulsion. The toxicity of Syzygium aromaticum (clove) essential oil nanoemulsion was evaluated against the population of Tribolium castaneum in terms of LC50 (lethal concentration), which was determined to be 112.93 ppm. The impact of the clove essential oil nanoemulsion formulated at LC50 on wheat germination and seedling growth was assessed using a pot test. Results showed that the treatment inhibited wheat seedling growth and reduced the overall growth rate. Additionally, the metabolites of adult T. castaneum beetles were analyzed following exposure to a sub-lethal concentration (LC20) of the clove oil nanoemulsion. The sub-lethal dose significantly decreased glycogen and glucose levels in all adult beetles while increasing invertase activity and total protein in resistant populations throughout the exposure period. These metabolic changes highlight the biochemical impact of the nanoemulsion. A molecular docking study was conducted to predict the mode of action of the major components of the essential oil and nanoemulsion, namely eugenol and α-humulene, at the binding site of the enzyme alkaline acid phosphatase of Tribolium castaneum. The results provide insights into the molecular interactions between insect-plant compounds and their effects at the biochemical level. These findings suggest the potential of clove essential oil nanoemulsion as a natural, eco-friendly solution for sustainable pesticide management in stored grain facilities. Furthermore, the study emphasizes the need to understand the side effects on both animals and humans to ensure safe applications.

1 May 2026 in Current Molecular Medicine
Verified
Journal Article
Closed access
PDF file
Farhan IkhtiarFarhan Ikhtiar
Farhan Ikhtiar
AJADIL JAMAL
ADIL JAMAL
AAAmina Arif
Amina Arif
MSMuhammad Naveed Shahid
Muhammad Naveed Shahid
SBSyed M. Safeer Mehdi Bokhari
Syed M. Safeer Mehdi Bokhari
Hemochromatosis is an autosomal recessive iron overload disorder. It occurs due to a failure in the hepcidin response, leading to systemic iron overload. The high iron levels in the plasma stored in various organs cause injury and permanent damage. There are two types of hemochromatosis: primary and secondary. In non- HFE hemochromatosis, mutations in the HJV, HAMP, TRF2, and SLC40A1 genes are implicated, with the associated condition classified as type I hemochromatosis. In contrast, juvenile hemochromatosis (type II hemochromatosis/ HFE II) is linked to mutations in the hemojuvelin gene or the antimicrobial peptide hepcidin. In this study, relevant literature in databases, including PubMed, MEDLINE records, Cochrane Central Register of Controlled Trials (CENTRAL), Google Scholar, and Embase, was searched. Our study inclusion criteria encompassed both experimental and observational studies or a combination of both, with data derived from the human population. The exclusion criteria included animal models, observational studies, and unpublished data. Hepcidin is usually up-regulated in response to high serum iron, but it is unexpectedly low in patients with hemochromatosis because of mutations in HFE, hemojuvelin (JH), and transferrin receptor 2 (TfR2). TfR2, expressed by hepatocytes, is mutated in hemochromatosis type III. Future research directions include exploring the molecular mechanisms underlying the effects of the TFR2 gene variant on iron homeostasis and liver damage and investigating potential therapeutic targets for treating hemochromatosis-related liver disease. Additionally, further epidemiological and modern genetic engineering studies are needed to better understand the prevalence and impact of hemochromatosis on liver health in different populations.

2 November 2026 in ADMET and DMPK
Verified
Journal Article
Open access
PDF file
MFMuhammad Usman Farooq
Muhammad Usman Farooq
MAMujahid Abbas
Mujahid Abbas
Farhan IkhtiarFarhan Ikhtiar
Farhan Ikhtiar
LILaraib Zafar Iqbal
Laraib Zafar Iqbal
SKSafiullah Khan
Safiullah Khan
Background and purpose: Spider venom peptides are chemically diverse scaffolds with high potency, selectivity and structural stability, but native toxins often require optimization for therapeutic use. This review examines strategies for reprogramming spider venom peptides to improve selectivity, stability, safety and delivery. Experimental approach: Recent literature on venomics, sequence redesign, motif grafting, lipidation, terminal modification, peptidomimetic tuning, ligation and synthesis and delivery engineering was examined. Key results: Inhibitor cystine knot peptides provide robust scaffolds for ion-channel modulation, while linear peptides, enzymes and acylpolyamines broaden chemical space. Transcriptomics, proteomics, computational mining and machine learning accelerate discovery and functional prioritization. Rational substitutions, hybridization, lipidation, terminal editing, synthesis and nanocarrier engineering can improve pharmacological and developability profiles, although trade-offs remain. Conclusion: Spider venom research is moving from toxin discovery toward developability-focused reprogramming. Future progress requires integrated structural biology, medicinal chemistry, scalable synthesis and delivery science to address short half-life, off-target activity, manufacturability and venom scarcity.

1 July 2025 in Brazilian Journal of Science
Verified
Journal Article
Open access
PDF file
Farhan IkhtiarFarhan Ikhtiar
Farhan Ikhtiar
LILaraib Zafar Iqbal
Laraib Zafar Iqbal
MFMuhammad Usman Farooq
Muhammad Usman Farooq
MFMuhammad Faheem Faraz
Muhammad Faheem Faraz
MQMuhammad Faizan Qadir
Muhammad Faizan Qadir
UNUme Aiymen Nisar
Ume Aiymen Nisar
Hemochromatosis is an autosomal recessive iron overload disorder. The TFR2 gene variant rs7385804 has been implicated in hemochromatosis, but its role in the Pakistani population remains unexplored. This study intended to examine the association of the TFR2 gene variant rs7385804 with hemochromatosis in Pakistani individuals. We employed a case-control study design, recruiting 200 hemochromatosis patients and 200 healthy controls from the Pakistani population. Deoxyribonucleic acid was isolated from blood samples using the phenol-chloroform method. Sanger sequencing and Tetra-ARMS PCR were used to identify the TFR2 genes and their variant rs7385804. Our results showed a significant association between the TFR2 gene variant rs7385804 and hemochromatosis in the Pakistani population (p < 0.001). The rate of the abnormal alleles was (35%) higher than that of the control (15%). Sanger sequencing confirmed the presence of the variant in 70% of patients, while Tetra-ARMS PCR showed 90% concordance with sequencing results. This study demonstrates the utility of Sanger sequencing and Tetra-ARMS PCR in detecting the TFR2 gene variant rs7385804 in the Pakistani population. Our findings suggest that this variant may serve as a genetic marker for hemochromatosis in this population. More research is required to validate these outcomes and discover the clinical consequences of this association.